Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Pfizer, BioNTech Jump After Fast-Track Designation; Moderna a Buy

Published 07/13/2020, 11:10 AM
Updated 07/13/2020, 11:11 AM
© Reuters.
PFE
-
JEF
-
CSGP
-
MRNA
-

By Christiana Sciaudone

Investing.com --  The race for a Covid-19 vaccine is heating up as the virus spreads unrelentingly in the U.S. and Brazil. 

Pfizer (NYSE:PFE) shares rose 4.7% and BioNTech was up 18% on Monday after two Covid-19 vaccine candidates were granted fast-track designation from the Food and Drug Administration.

Meanwhile, Jefferies initiated Moderna (NASDAQ:MRNA) Inc. with a buy rating as its experimental vaccine for Covid-19 could generate sales of more than $5 billion a year, Bloomberg reported. Moderna shares jumped 13.5%, to $71.08 in mid-morning trading.

Jefferies (NYSE:JEF) analyst Michael Yee said a 30,000 person late-stage study will start this month and should get “at least” an emergency use authorization by early next year. Yee set a price target of $90, Bloomberg said.  MRNA has 12 buys, two holds and no sell ratings, according to data compiled by Investing.com, with an average price target of $85.36.

The U.S. and Brazil accounted for half of the new daily coronavirus cases on Sunday, more than 111,000, the World Health Organization said Monday. 

Moderna will also replace CoStar Group (NASDAQ:CSGP) in the NASDAQ-100 Index, the NASDAQ-100 Equal Weighted Index, and the NASDAQ-100 Ex-Tech Sector Index prior to market open on Monday, July 20.  

Pfizer said that if the ongoing studies are successful, and the vaccine candidate receives regulatory approval, the companies expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021.






Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.